ArticleAnnals of nuclear medicine2022
Clinical impact of amyloid PET using
Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Association of global gray matter volume and cortical thickness with cognitive function stratified by amyloid PET status.Annals of nuclear medicine · 2026Article
- Sequential scans ofJapanese journal of radiology · 2026Article
- Comparative evaluation of CortexID and VIZCalc software in brain amyloid PET: a retrospective study of 116 cases.Annals of nuclear medicine · 2026Article
- Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Comparison of visual and analytic methods of Alzheimer's disease pathologic staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.Annals of nuclear medicine · 2025Article
- TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers.Frontiers in cellular neuroscience · 2025Review
- Interrater agreement and variability in visual reading of [18F] flutemetamol PET images.Annals of nuclear medicine · 2025Article
- The Taiwan-ADNI workflow toward integrating plasma p-tau217 into prediction models for the risk of Alzheimer's disease and tau burden.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer's disease pathology in the eye clinic.Alzheimer's research & therapy · 2024Observational
- Novel β-amyloid PET Imaging Study of [ACS omega · 2024Article
- Incremental value of amyloid PET in a tertiary memory clinic setting in China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease.Fukushima journal of medical science · 2023Article
- Development of software for measuring brain amyloid accumulation usingBrain and behavior · 2023Article
- Imaging of Tauopathies with PET Ligands: State of the Art and Future Outlook.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAmyloid positron emission tomography (PET) can reliably detect senile plaques and fluorinated ligands are approved for clinical use. However, the clinical impact of amyloid PET imaging is still under investigation. The aim of this study was to evaluate the diagnostic impact and clinical utility in patient management of amyloid PET using
methodsNinety-nine patients suspected of having AD underwent
resultsVisual interpretation obtained 48 positive and 51 negative PET scans. The amyloid PET results changed the AD and non-AD diagnosis in 39 of 99 patients (39.3%). The change rates of 26 of the 54 patients (48.1%) with a pre-scan AD diagnosis were significantly higher than those of 13 of the 45 patients with a pre-scan non-AD diagnosis (χ
conclusionAmyloid PET using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.